Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#151 / 200 Total
ITOS - ITeos Therapeutics Inc - Stock Price Chart
TickerITOS [NASD, RUT]
CompanyITeos Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap648.72MEPS (ttm)-3.78
P/E-EPS this Y-40.83%
Forward P/E-EPS next Y-25.92%
PEG-EPS past 5Y-40.62%
P/S-EPS next 5Y-
P/B1.19EPS Q/Q-144.88%
Dividend-Sales Q/Q-100.00%
Insider Own20.36%Inst Own77.87%
Insider Trans0.00%Inst Trans-2.43%
Short Float7.20%EarningsMay 10/b
Analyst Recom1.00Target Price35.40
Avg Volume400.31K52W Range8.20 - 18.75
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gall MatthewChief Financial OfficerOct 12 '23Buy8.375,00041,85019,429Oct 12 05:09 PM
Boxer Capital, LLCAug 23 '23Sale16.26350,0005,692,6731,804,058Aug 25 09:28 PM
CTCX - Carmell Corp - Stock Price Chart
TickerCTCX [NASD]
CompanyCarmell Corp
CountryUSA
IndustryBiotechnology
Market Cap48.30MEPS (ttm)-0.56
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S12.95EPS next 5Y-
P/B2.57EPS Q/Q-1554.12%
Dividend-Sales Q/Q-
Insider Own30.36%Inst Own17.70%
Insider Trans1.01%Inst Trans4.73%
Short Float0.19%Earnings-
Analyst Recom-Target Price-
Avg Volume7.33K52W Range1.70 - 13.31
Carmell Corp. is a regenerative medicine biotech company, which focuses on leveraging its core platform technology plasma based bioactive material to stimulate tissue repair or growth after severe injury, disease or aging. Its products include Bone Healing Accelerant and Tissue Healing Accelerant. The company was founded on November 5, 2008 and is headquartered in Pittsburgh, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sturgeon Patrick ADirectorDec 15 '23Buy3.947392,9086,727Dec 18 05:11 PM
Gregory KathrynDirectorDec 15 '23Buy3.947392,9086,727Dec 18 05:10 PM
Anderson David WDirectorDec 15 '23Buy3.947392,9086,727Dec 18 05:10 PM
Spenlehauer GillesDirectorDec 15 '23Buy3.945912,3265,381Dec 18 05:13 PM
Frisch Scott M.DirectorDec 15 '23Buy3.945912,3265,381Dec 18 05:12 PM
GSM - Ferroglobe Plc - Stock Price Chart
TickerGSM [NASD]
CompanyFerroglobe Plc
CountryUnited Kingdom
IndustryOther Industrial Metals & Mining
Market Cap1.12BEPS (ttm)0.34
P/E17.76EPS this Y-73.94%
Forward P/E9.82EPS next Y229.73%
PEG0.89EPS past 5Y11.57%
P/S0.68EPS next 5Y20.00%
P/B1.51EPS Q/Q-109.76%
Dividend0.83%Sales Q/Q-2.25%
Insider Own40.16%Inst Own47.22%
Insider Trans0.00%Inst Trans5.84%
Short Float1.37%EarningsMay 14/a
Analyst Recom1.00Target Price10.00
Avg Volume1.64M52W Range4.18 - 6.78
Ferroglobe PLC is a holding company, which engages in the production of silicon and specialty metals. Its products include silicon metal, manganese alloys, ferrosilicon, calcium silicon, and electrodes. It operates through the following segments: North America Silicon Metal, North America Silicon Alloys, Europe Manganese, Europe Silicon Metal, Europe Silicon, South Africa Silicon Metal, South Africa Silicon Alloys, and Other. The company was founded on February 5, 2015 and is headquartered in London, the United Kingdom.
ATAI - ATAI Life Sciences N.V. - Stock Price Chart
TickerATAI [NASD]
CompanyATAI Life Sciences N.V.
CountryGermany
IndustryBiotechnology
Market Cap343.19MEPS (ttm)-0.21
P/E-EPS this Y-181.71%
Forward P/E-EPS next Y-1.99%
PEG-EPS past 5Y44.19%
P/S1225.68EPS next 5Y-
P/B1.53EPS Q/Q20.97%
Dividend-Sales Q/Q-100.00%
Insider Own30.64%Inst Own7.67%
Insider Trans-0.20%Inst Trans11.11%
Short Float5.43%EarningsMay 15/b
Analyst Recom1.00Target Price9.00
Avg Volume1.56M52W Range1.02 - 2.85
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rao SrinivasSee RemarksApr 02 '24Sale1.8561,640114,034113,360Apr 04 06:11 PM
Kirpekar SahilChief Business OfficerApr 02 '24Sale1.8535,80166,23264,199Apr 04 06:11 PM
Johnson Anne NagengastChief Financial OfficerApr 02 '24Sale1.8527,41050,70873,590Apr 04 06:11 PM
Brand FlorianSee RemarksNov 16 '23Buy1.1620,00023,120130,000Nov 20 09:17 AM
Brand FlorianSee RemarksSep 13 '23Buy1.4540,00057,968110,000Sep 14 04:30 PM
VHI - Valhi, Inc. - Stock Price Chart
TickerVHI [NYSE, RUT]
CompanyValhi, Inc.
CountryUSA
IndustryChemicals
Market Cap514.03MEPS (ttm)0.02
P/E865.24EPS this Y433.33%
Forward P/E5.28EPS next Y145.71%
PEG64.09EPS past 5Y-
P/S0.26EPS next 5Y13.50%
P/B0.56EPS Q/Q259.22%
Dividend1.76%Sales Q/Q7.69%
Insider Own91.54%Inst Own3.71%
Insider Trans0.00%Inst Trans12.13%
Short Float1.80%EarningsMay 09/a
Analyst Recom5.00Target Price11.00
Avg Volume6.35K52W Range10.80 - 17.61
May-09-24 04:28PM Valhi: Q1 Earnings Snapshot (Associated Press Finance) +5.56%
04:18PM VALHI REPORTS FIRST QUARTER 2024 RESULTS (GlobeNewswire)
Mar-07-24 10:52PM VHI Stock Earnings: Valhi Reported Results for Q4 2023 (InvestorPlace) +7.13%
05:07PM Valhi: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM VALHI REPORTS FOURTH QUARTER 2023 RESULTS (GlobeNewswire)
Feb-29-24 04:15PM VALHI DECLARES QUARTERLY DIVIDEND (GlobeNewswire)
Nov-06-23 06:12PM Valhi: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM VALHI REPORTS THIRD QUARTER 2023 RESULTS (GlobeNewswire)
Nov-02-23 04:15PM VALHI DECLARES QUARTERLY DIVIDEND (GlobeNewswire)
Aug-06-23 09:46AM Valhi's (NYSE:VHI) Returns On Capital Tell Us There Is Reason To Feel Uneasy (Simply Wall St.)
Valhi, Inc. is a holding company, which engages in the manufacture and marketing of titanium dioxide pigments. It operates through the following segments: Chemicals, Component Products, and Real Estate Management and Development. The Chemicals segment produces and markets titanium dioxide pigments for paints, plastics, paper, fibers, and ceramics. The Component Products segment includes security products used in the recreational transportation, postal, office and institutional furniture, tool storage, healthcare, and a variety of other industries. The Real Estate Management and Development segment covers real estate management and development. The company was founded in 1987 and is headquartered in Dallas, TX.
SLS - SELLAS Life Sciences Group Inc - Stock Price Chart
TickerSLS [NASD]
CompanySELLAS Life Sciences Group Inc
CountryUSA
IndustryBiotechnology
Market Cap84.89MEPS (ttm)-1.11
P/E-EPS this Y33.21%
Forward P/E-EPS next Y15.64%
PEG-EPS past 5Y61.44%
P/S-EPS next 5Y-
P/B8.54EPS Q/Q54.70%
Dividend-Sales Q/Q-
Insider Own0.69%Inst Own18.30%
Insider Trans0.00%Inst Trans-11.61%
Short Float12.19%EarningsMay 14/a
Analyst Recom1.00Target Price5.75
Avg Volume1.54M52W Range0.50 - 1.91
May-14-24 10:54PM SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024 (InvestorPlace)
04:05PM SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-24 08:35AM SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level (GlobeNewswire)
Apr-29-24 08:45AM SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study (GlobeNewswire) -17.12%
Mar-28-24 10:54PM SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023 (InvestorPlace)
04:05PM SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma (PR Newswire)
Mar-26-24 07:35AM SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study (GlobeNewswire)
Mar-19-24 04:05PM SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:47AM SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET (GlobeNewswire)
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
RENT - Rent the Runway Inc - Stock Price Chart
TickerRENT [NASD, RUT]
CompanyRent the Runway Inc
CountryUSA
IndustryApparel Retail
Market Cap88.47MEPS (ttm)-16.97
P/E-EPS this Y39.39%
Forward P/E-EPS next Y2.94%
PEG-EPS past 5Y8.41%
P/S0.30EPS next 5Y-
P/B-EPS Q/Q12.92%
Dividend-Sales Q/Q0.53%
Insider Own57.55%Inst Own30.36%
Insider Trans-27.91%Inst Trans-73.19%
Short Float26.06%EarningsApr 10/a
Analyst Recom1.67Target Price20.50
Avg Volume1.41M52W Range4.46 - 58.00
Rent the Runway, Inc. provides online ready-to-wear and contemporary designer apparel services. It rents designer dresses, gowns, and accessories for women. Its online platform enables women to search and book dresses and accessories for rental for various occasions, including parties, vacations, weddings, dates, and birthdays and also sells intimates, fashion solutions, lingerie, shape wear, tights, beauty products, jewelry, and shoes online. The company was founded by Jennifer Y. Hyman and Jennifer Carter Fleiss in November 2008 and is headquartered in Brooklyn, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hyman JenniferChair, CEO & PresidentMay 02 '24Sale12.284,60056,490164,884May 06 08:42 PM
Case BeckySVP, EngineeringMay 02 '24Sale12.2890711,14030,379May 06 08:47 PM
Thacker SiddharthChief Financial OfficerMay 02 '24Sale12.285396,62054,703May 06 08:43 PM
Tam Sarah KChief Merchant OfficerMay 02 '24Sale12.283354,11435,455May 06 08:45 PM
Schembri CaraChief Legal & Admin. OfficerMay 02 '24Sale12.283113,82032,214May 06 08:45 PM
NYXH - Nyxoah SA - Stock Price Chart
TickerNYXH [NASD]
CompanyNyxoah SA
CountryBelgium
IndustryMedical Instruments & Supplies
Market Cap294.34MEPS (ttm)-1.63
P/E-EPS this Y-7.64%
Forward P/E-EPS next Y-4.33%
PEG-EPS past 5Y-27.28%
P/S53.03EPS next 5Y-
P/B3.12EPS Q/Q8.75%
Dividend-Sales Q/Q180.07%
Insider Own67.69%Inst Own12.85%
Insider Trans0.00%Inst Trans-
Short Float2.84%EarningsMay 14/a
Analyst Recom1.50Target Price20.06
Avg Volume44.45K52W Range4.00 - 20.00
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.
ICCM - Icecure Medical Ltd - Stock Price Chart
TickerICCM [NASD]
CompanyIcecure Medical Ltd
CountryIsrael
IndustryMedical Devices
Market Cap54.88MEPS (ttm)-0.32
P/E-EPS this Y10.16%
Forward P/E-EPS next Y10.72%
PEG-EPS past 5Y-0.26%
P/S16.99EPS next 5Y-
P/B4.51EPS Q/Q48.10%
Dividend-Sales Q/Q1281.68%
Insider Own56.16%Inst Own0.50%
Insider Trans0.00%Inst Trans-
Short Float1.39%EarningsApr 03/b
Analyst Recom1.00Target Price3.30
Avg Volume481.54K52W Range0.52 - 1.57
May-07-24 08:30AM Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense, Adding to Continued Positive Data Published Globally (PR Newswire)
Apr-30-24 10:30AM As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
Apr-18-24 11:07AM IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA (Zacks)
Apr-15-24 08:35AM IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer (PR Newswire) +8.00%
Apr-04-24 09:28AM IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-03-24 12:52PM ICCM Stock Earnings: Icecure Medical Meets EPS, Beats Revenue for Q4 2023 (InvestorPlace) -6.72%
08:30AM IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance (PR Newswire)
Apr-02-24 08:30AM IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes (PR Newswire)
Mar-27-24 08:30AM IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 (PR Newswire)
Mar-19-24 08:30AM IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy (PR Newswire)
IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.
TBBB - BBB Foods Inc - Stock Price Chart
TickerTBBB [NYSE]
CompanyBBB Foods Inc
CountryMexico
IndustryDiscount Stores
Market Cap2.88BEPS (ttm)-
P/E-EPS this Y106.64%
Forward P/E58.79EPS next Y179.07%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own20.86%
Insider Trans-Inst Trans-
Short Float-EarningsApr 25/a
Analyst Recom2.14Target Price26.98
Avg Volume831.70K52W Range18.71 - 26.41
BBB Foods, Inc. engages in the provision of a limited assortment of products that cover the daily grocery needs. It offers the grocery hard discount model where products offered are generally value for money. The company was founded by K. Anthony Hatoum on July 9, 2004 and is headquartered in Mexico City.
11011121314151617181920